XISTA Science Ventures

What XISTA Science Ventures does

XISTA Science Ventures is a European early-stage venture capital firm founded in 2017 (operating since 2018) and headquartered at the Institute of Science and Technology Austria (ISTA) campus in Klosterneuburg, Austria. The firm manages two EuVECA-registered science venture funds with €96 million in combined AUM and 29 portfolio companies spanning life sciences, digital technologies, and industrial innovation. XISTA's core function is to deploy early-stage capital alongside hands-on operational support, strategic guidance, and access to ISTA's research infrastructure for scientific founders—particularly academic spin-offs from ISTA, TU Wien, and TUM. The firm operates a horizontal segmentation approach, targeting scientific founders, deep tech/hard science startups, and co-investor syndicate partners.

XISTA sources deals through its online pitch form, direct outreach, and a privileged institutional network. Its investment process involves structured due diligence, deal structuring, and ongoing board-level support. Portfolio holdings span antibody-drug conjugates (VALANX Biotech, with €3M from FUJIFILM), DNA origami diagnostics (Amplifold, €5M seed), AI model compression (Ora Computing, €3.5M seed), microbeam radiation therapy (CollimateHealth, €6M seed), quantum light chips for AR (VitreaLab, $11M Series A), AI-powered 3D digital twins (AVES Reality, €2.7M seed), nanomechanical infrared analyzers (Invisible-Light Labs, €1.5M pre-seed with Bruker Optics partnership), and AI-driven factory design (factorymaker, €1.1M pre-seed). The firm claims approximately €700 million in ecosystem value creation and 450 jobs generated, with €30 million deployed into early-stage innovation.

Revenue is generated via management fees and carried interest on the two EuVECA funds. XISTA Science Ventures Management GmbH is registered as an Alternative Investment Fund Manager (AIFM) with the Austrian Financial Market Authority and receives backing from InnovFin Equity under the EU's Horizon 2020 and the European Fund for Strategic Investments (EFSI). Leadership combines scientific depth (PhDs in chemistry and molecular biology from Cambridge MRC, ETH Zurich, and Harvard) with investment and operating experience from MIT Sloan, Boston Consulting Group, McKinsey, European Investment Fund, Safeguard Scientifics, and Novartis Corporate IP.

Name

XISTA Science Ventures

Legal name

xista science ventures Management GmbH

Website

https://xista.vc

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

XISTA Science Ventures is an Austria-based early-stage venture capital firm managing €96 million across two EuVECA-registered funds, backing 29 science-based startups from institutions like ISTA, TU Wien, and TUM across life sciences, AI, photonics, and industrial tech.

Ownership category

akta.pro rank

Product category

Venture Capital / Early-Stage Science Investing

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investors, Nec (6799)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital
• Deep tech investing
• Science startup funding
• Academic spin-offs
• Early-stage equity

Headquarters

HQ city

Klosterneuburg

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Venture Capital Fund Management: XISTA generates returns through equity investments in early-stage science startups. The firm deploys capital from its EuVECA-registered venture funds into portfolio companies and aims to create value through exits. Revenue is generated via carried interest, management fees, and portfolio company equity appreciation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

XISTA Science Ventures is an early-stage venture capital firm that invests equity capital from two EuVECA-registered science venture funds (Fund I and Fund II, totaling €96 million AUM) into science-based startups spun out of top European research institutions. The firm partners with founders from pre-seed through Series A, providing capital alongside hands-on operational support, board-level strategic guidance, access to the ISTA research ecosystem, and introductions to industry partners, customers, and follow-on investors. Core focus areas are life sciences, digital technologies (including AI), and industrial innovation, with 29 portfolio companies and an estimated €700 million of ecosystem value created.

Differentiator

Problem solved

Functional benefit

Products and services

• xista science venture (EuVECA) — Fund I EuVECA-registered venture capital fund managed by xista science ventures Management GmbH, providing equity capital to early-stage science-based startups, with deployment focused on life sciences, digital technologies, and industrial innovation. Available to qualified limited-partner investors.
• xista science venture II (EuVECA) — Fund II Second EuVECA-registered venture capital fund managed by xista science ventures Management GmbH, providing follow-on and new equity investments to early-stage science-based startups across the XISTA ecosystem. Available to qualified limited-partner investors.

Quantifiable outcome

• €700 million value created across the XISTA ecosystem
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered flagship.

• FUJIFILM CorporationflagshipStrategic or Co-development PartnerFUJIFILM invested €3 million in VALANX Biotech (March 2026) to advance next-generation antibody-drug conjugate (ADC) therapeutics. The partnership strengthens manufacturing capabilities in the rapidly growing ADC field. FUJIFILM is building a full manufacturing ecosystem for ADCs, with a new integrated ADC manufacturing service planned for Japan in 2027.
• Bruker OpticsflagshipStrategic or Co-development PartnerBruker Optics, a leading global provider of analytical instruments, entered a strategic partnership with XISTA portfolio company Invisible-Light Labs in 2025 to co-market the EMILIE™ NEMS-FTIR analyzer globally. Bruker is the market leader in FT-IR spectroscopy, and the co-branded system (BRKR-EMILIE) expands international commercialization of Invisible-Light Labs' technology.
• Institute of Science and Technology Austria (ISTA)flagshipStrategic or Co-development PartnerXISTA is embedded in the innovation ecosystem around ISTA. Multiple portfolio companies (Ora Computing, Syntropic Medical, Neurolentech) are spin-offs from ISTA. XISTA provides technology transfer support and access to ISTA's research infrastructure, lab space, and talent pipeline.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Matterwave Ventures: Munich-based early-stage VC focused on deep-tech and hard science startups. Repeated co-investor with XISTA in Amplifold (€5M seed), AVES Reality (€2.7M seed), and other deals, with highly overlapping thesis in industrial and science-based companies.
• High-Tech Gründerfonds (HTGF): Germany's most active early-stage VC financing deep-tech, life sciences, and digital-tech companies. Co-invested with XISTA in CollimateHealth's €6M seed round and is the closest comparable German science-focused seed/Series A investor.
• Constructor Capital: Switzerland-based early-stage VC investing in Deep Tech, Software Tech, and Knowledge Tech at seed and Series A. Co-invested with XISTA in Ora Computing (€3.5M seed) and VitreaLab ($11M Series A), with comparable ticket sizes and stage focus.
• Vsquared Ventures: Munich-based deep-tech VC backing science-driven companies across new compute, energy, mobility, and health. Comparable European science-VC peer with similar academic spin-off sourcing and €100M+ fund sizes.
• LIFTT Italian Venture Capital: Italy-based deep-tech VC bridging frontier academic research with venture capital discipline. Led VitreaLab's $11M Series A alongside XISTA, with comparable academic-spin-out thesis in photonics and quantum.

Regional players

• aws Gründerfonds: Austrian seed-to-Series A/B fund of €72M supporting domestic startups. Co-invested with XISTA in Invisible-Light Labs and VitreaLab, with strong Austrian ecosystem overlap but a broader sector mandate (not strictly science-focused).

Broad incumbents

• Earlybird Venture Capital: One of Europe's largest early-stage VCs with deep-tech and health franchises (Earlybird Health). Larger and more diversified than XISTA, but overlaps on deep-tech seed/Series A and provides a useful incumbent benchmark for European science investing.
• ARCH Venture Partners: US-based science-focused VC backing early-stage deep-tech and biotech companies out of university labs (analogous to XISTA's ISTA model). Far larger scale but the most established science-VC reference point globally.
• Lux Capital: US science and technology VC investing in companies built on breakthrough research across biology, engineering, and computing. Comparable science-VC thesis with much larger fund sizes; useful cross-Atlantic benchmark.

Emerging players

• Forbion: European life sciences-focused VC with deep biotech and medtech franchises. Relevant peer for XISTA's life-sciences book (VALANX, HEPHAISTOS, Syntropic) although typically invests at later stages than XISTA.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments42 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XISTA Science Ventures